| 降脂药物的肝脏毒性及其防治策略研究进展 |
| 投稿时间：2013-10-29 修订日期：2014-06-11 点此下载全文 |
| 引用本文：徐岩成,方一杰,阎澜,姜远英,曹永兵.降脂药物的肝脏毒性及其防治策略研究进展[J].药学实践杂志,2014,32(6):412~415,464 |
| 摘要点击次数: 919 |
| 全文下载次数: 230 |
|
|
| 中文摘要:肝脏毒性是降血脂药物治疗常见的毒副作用之一,其发生机制尚不完全清楚,大多数降血脂药物的毒副作用都是剂量依赖性的,而且在停药后都有明显的缓解与改善。高龄以及慢性疾病等都是诱发降血脂药物肝脏毒性的潜在因素。降血脂药物的肝脏损伤治疗暂无统一规范,临床应对策略以停药、非特异性保肝和对症治疗为主。研发低毒性或具有保肝作用的降血脂药物,尤其是中药及中药制剂是一个具有良好前景的发展方向。 |
| 中文关键词:高血脂 药物 肝脏毒性 |
| |
| Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies |
|
|
| Abstract:Hepatotoxicity is one of the most common adverse reactions during anti-hyperlipidemia treatment. Mechanisms of anti-hyperlipidemia drug-induced hepatotoxicity are not clear yet, but most of the toxic reactions are dose-related hypersensitivity and could be released after drug withdrawal. It is accepted that clinical risk factors for the development of hepatotoxicity during anti-hyperlipidemia treatment are high age and chronic illnesses. Treatment of anti-hyperlipidemia drug-induced hepatotoxicity has not been unified and most of the treatments are non-specific and symptomatic. Researching hypotoxicity and hepatoprotection antihyperlipidemia drug, especially TCM and pharmaceutics will become a promising direction. |
| keywords:hyperlipidemia drug hepatotoxicity |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
